Tetraphase Pharmaceuticals (TTPH - Free Report) announced that it has begun dosing in the phase III IGNITE4 study on its lead antibiotic candidate, eravacycline.
IGNITE4 is evaluating the efficacy and safety of twice-daily intravenous (IV) eravacycline compared to meropenem for the treatment of complicated intra-abdominal infections (cIAI).
Eravacycline is a novel antibiotic that is being developed for the treatment of serious and life-threatening bacterial infections, including those caused by multidrug-resistant (MDR) pathogens. It is currently in phase III trials.
Tetraphase expects to present top-line data from IGNITE4 in the fourth quarter of 2017.
Under the IGNITE program, Tetraphase has already completed two phase III studies (n>1300) – IGNITE1 for cIAI and IGNITE2 for complicated urinary tract infections (cUTI).
The company plans to submit a new drug application (NDA) for IV eravacycline for the treatment of cIAI based on data from IGNITE1 and IGNITE4, assuming positive results from the latter. Moreover, the company plans to initiate IGNITE3, a phase III trial to evaluate once-daily IV eravacycline for the treatment of complicated cUTI. Tetraphase is also conducting a phase I clinical program on an oral dosing regimen of eravacycline.
Apart from eravacycline, Tetraphase’s pipeline also includes TP-271 and TP-6076. Both the candidates are presently in phase I clinical trials.
TETRAPHASE PHAR Price
Zacks Rank & Stocks to Consider
Tetraphase carries a Zacks Rank #2 (Buy). Other favorably placed stocks in the health care sector are Amarin Corporation plc (AMRN - Free Report) , BioMarin Pharmaceutical Inc. (BMRN - Free Report) and Exelixis, Inc. (EXEL - Free Report) . While BioMarin and Exelixis carry a Zacks Rank #1 (Strong Buy), Amarin holds Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
BioMarin’s loss estimates narrowed from 28 cents to 25 cents for 2016 and from $1.16 to $1.11 for 2017 over the last 60 days.
Exelixis’s loss estimates narrowed from 76 cents to 63 cents for 2016 and from 22 cents to a gain of 3 cents for 2017 over the last 60 days. The company has posted a positive surprise twice in the four trailing quarters with an average beat of 9.1%. Its share price has skyrocketed over 100% year to date.
Amarin’s loss narrowed from 53 cents to 40 cents for 2016 and from 36 cents to 27 cents for 2017 over the last 60 days. The company’s share price has rallied 56.6% year to date.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>